Joseph Schwartz
Stock Analyst at Leerink Partners
(4.95)
# 142
Out of 4,988 analysts
1269
Total ratings
54.4%
Success rate
33%
Average return
Main Sectors:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals | Initiated Coverage: Buy | $32 | $17.45 | +83.38% | 1 | Sep 18, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Buy | $33 | $14.51 | +127.43% | 71 | Sep 18, 2026 | |
| PHVS Pharvaris | Rated: Buy | $38 → $65 | $36.37 | +78.72% | 38 | Sep 10, 2026 | |
| GOSS Gossamer Bio | Upgraded: Buy | $6 → $1 | $10.73 | -90.68% | 36 | Jul 27, 2026 | |
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $80 | $29.48 | +171.37% | 1 | Jun 24, 2026 | |
| QURE uniQure | Reiterated: Buy | $60 → $70 | $44.00 | +59.09% | 62 | Jun 17, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Buy | $52 | $45.32 | +14.74% | 50 | Jun 16, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $225 → $305 | $236.72 | +28.84% | 72 | Jun 2, 2026 | |
| FULC Fulcrum Therapeutics | Downgraded: Hold | $24 → $4 | $3.76 | +6.38% | 37 | Jun 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $60 → $62 | $63.94 | -3.03% | 90 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $1 → $9 | $5.05 | +78.22% | 23 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $8.95 | +179.33% | 1 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 → $120 | $53.05 | +126.20% | 32 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27.74 | $13.03 | +112.89% | 1 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $25 | $4.35 | +474.71% | 31 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $22.52 | +122.02% | 9 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 | $20.11 | -25.41% | 107 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $62.76 | - | 87 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.09 | - | 50 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $2 | $0.303 | +560.07% | 31 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $8.91 | +124.47% | 45 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $16 | $16.90 | -5.33% | 52 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $5 → $14 | $12.24 | +14.38% | 29 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $115 | $96.47 | +19.21% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $54 | $65.37 | -17.39% | 33 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $120.00 | - | 63 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.79 | n/a | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.85 | n/a | 29 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $1.19 | n/a | 29 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $2.95 | n/a | 19 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $14 | $278.06 | n/a | 1 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $150 → $30 | $8.03 | n/a | 10 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $40 → $34 | $44.44 | n/a | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $143.00 | n/a | 28 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $385.65 | n/a | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.20 | n/a | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $31 → $4 | $49.45 | n/a | 16 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $349.67 | n/a | 1 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53.19 | $217.45 | n/a | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $30 | $0.968 | n/a | 2 | Jan 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 → $23 | $12.14 | n/a | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $12 | $1.83 | n/a | 5 | Sep 26, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $121 → $126 | $494.63 | n/a | 4 | Apr 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.35 | n/a | 11 | Nov 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.0885 | n/a | 5 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $14 | $4.00 | n/a | 6 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $0.8055 | n/a | 1 | Mar 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $664 | $784.85 | n/a | 7 | Oct 26, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $512 → $425 | $215.50 | n/a | 3 | Sep 15, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $8 | $68.78 | n/a | 3 | May 19, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.63 | n/a | 6 | Oct 30, 2013 |
Eloxx Pharmaceuticals
Sep 18, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $17.45
Upside: +83.38%
Ultragenyx Pharmaceutical
Sep 18, 2026
Reiterated: Buy
Price Target: $33
Current: $14.51
Upside: +127.43%
Pharvaris
Sep 10, 2026
Rated: Buy
Price Target: $38 → $65
Current: $36.37
Upside: +78.72%
Gossamer Bio
Jul 27, 2026
Upgraded: Buy
Price Target: $6 → $1
Current: $10.73
Upside: -90.68%
Quince Therapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: $80
Current: $29.48
Upside: +171.37%
uniQure
Jun 17, 2026
Reiterated: Buy
Price Target: $60 → $70
Current: $44.00
Upside: +59.09%
Edgewise Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $52
Current: $45.32
Upside: +14.74%
Ascendis Pharma
Jun 2, 2026
Reiterated: Buy
Price Target: $225 → $305
Current: $236.72
Upside: +28.84%
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $24 → $4
Current: $3.76
Upside: +6.38%
BioMarin Pharmaceutical
May 18, 2026
Reiterated: Hold
Price Target: $60 → $62
Current: $63.94
Upside: -3.03%
May 15, 2026
Upgraded: Buy
Price Target: $1 → $9
Current: $5.05
Upside: +78.22%
May 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $8.95
Upside: +179.33%
May 15, 2026
Reiterated: Buy
Price Target: $160 → $120
Current: $53.05
Upside: +126.20%
Apr 6, 2026
Initiated Coverage: Buy
Price Target: $27.74
Current: $13.03
Upside: +112.89%
Mar 26, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $4.35
Upside: +474.71%
Mar 25, 2026
Reiterated: Buy
Price Target: $50
Current: $22.52
Upside: +122.02%
Mar 25, 2026
Reiterated: Hold
Price Target: $15
Current: $20.11
Upside: -25.41%
Jan 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $62.76
Upside: -
Dec 31, 2025
Reiterated: Hold
Price Target: n/a
Current: $2.09
Upside: -
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $2
Current: $0.303
Upside: +560.07%
Dec 15, 2025
Reiterated: Buy
Price Target: $20
Current: $8.91
Upside: +124.47%
Dec 3, 2025
Downgraded: Hold
Price Target: $12 → $16
Current: $16.90
Upside: -5.33%
Dec 3, 2025
Upgraded: Buy
Price Target: $5 → $14
Current: $12.24
Upside: +14.38%
Nov 10, 2025
Initiated Coverage: Buy
Price Target: $115
Current: $96.47
Upside: +19.21%
Oct 16, 2025
Reiterated: Hold
Price Target: $54
Current: $65.37
Upside: -17.39%
Sep 29, 2025
Reiterated: Buy
Price Target: n/a
Current: $120.00
Upside: -
Aug 15, 2025
Reiterated: Buy
Price Target: $25
Current: $3.79
Upside: n/a
Aug 7, 2025
Reiterated: Buy
Price Target: $10
Current: $2.85
Upside: n/a
Aug 12, 2024
Reiterated: Hold
Price Target: $1
Current: $1.19
Upside: n/a
May 7, 2024
Reiterated: Hold
Price Target: $10
Current: $2.95
Upside: n/a
Sep 7, 2023
Reiterated: Hold
Price Target: $14
Current: $278.06
Upside: n/a
Aug 18, 2023
Downgraded: Hold
Price Target: $150 → $30
Current: $8.03
Upside: n/a
Feb 3, 2023
Reiterated: Hold
Price Target: $40 → $34
Current: $44.44
Upside: n/a
Aug 5, 2022
Reiterated: Buy
Price Target: $30
Current: $143.00
Upside: n/a
Aug 4, 2022
Rated: Hold
Price Target: n/a
Current: $385.65
Upside: n/a
Jul 13, 2022
Reiterated: Buy
Price Target: n/a
Current: $8.20
Upside: n/a
Apr 5, 2022
Downgraded: Hold
Price Target: $31 → $4
Current: $49.45
Upside: n/a
May 7, 2021
Downgraded: Sell
Price Target: n/a
Current: $349.67
Upside: n/a
Apr 15, 2021
Reiterated: Buy
Price Target: $53.19
Current: $217.45
Upside: n/a
Jan 6, 2021
Downgraded: Hold
Price Target: $5 → $30
Current: $0.968
Upside: n/a
Nov 28, 2018
Initiated Coverage: Buy
Price Target: $37 → $23
Current: $12.14
Upside: n/a
Sep 26, 2017
Reiterated: Buy
Price Target: $10 → $12
Current: $1.83
Upside: n/a
Apr 3, 2017
Reiterated: Hold
Price Target: $121 → $126
Current: $494.63
Upside: n/a
Nov 13, 2016
Reiterated: Buy
Price Target: n/a
Current: $12.35
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $8
Current: $0.0885
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $12 → $14
Current: $4.00
Upside: n/a
Mar 8, 2016
Reiterated: Buy
Price Target: $24
Current: $0.8055
Upside: n/a
Oct 26, 2015
Reiterated: Buy
Price Target: $664
Current: $784.85
Upside: n/a
Sep 15, 2015
Reiterated: Buy
Price Target: $512 → $425
Current: $215.50
Upside: n/a
May 19, 2014
Initiated Coverage: Buy
Price Target: $20 → $8
Current: $68.78
Upside: n/a
Oct 30, 2013
Downgraded: Hold
Price Target: n/a
Current: $13.63
Upside: n/a